Neoadjuvant chemotherapy effective for small cell lung cancer in a nephrectomized patient

A 67-year-old man, who was nephrectomized due to renal cell cancer 4 years ago, was admitted to examine a mass shadow in the right middle lung field. He was diagnosed as small cell lung cancer with TBLB. Because of impaired renal function, he was treated with CBDCA (300 mg/m2, day 1), THP (30 mg/m2,...

Full description

Saved in:

Bibliographic Details
Published in:	Gan to kagaku ryoho Vol. 20; no. 14; p. 2235
Main Authors:	Toyoda, T, Okamoto, M, Fujii, M, Yonezu, S, Kumamoto, T, Umemoto, M, Saitoh, Y, Okamura, A
Format:	Journal Article
Language:	English Japanese
Published:	Japan 01-11-1993
Subjects:	Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Renal Cell - surgery Carcinoma, Small Cell - therapy Chemotherapy, Adjuvant Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Etoposide - administration & dosage Humans Lung Neoplasms - therapy Male Neoplasms, Second Primary Nephrectomy
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A 67-year-old man, who was nephrectomized due to renal cell cancer 4 years ago, was admitted to examine a mass shadow in the right middle lung field. He was diagnosed as small cell lung cancer with TBLB. Because of impaired renal function, he was treated with CBDCA (300 mg/m2, day 1), THP (30 mg/m2, day 1) and oral etoposide (25 mg/body, for 21 days) without any renal complications. After 3 courses of chemotherapy, the lung CT showed scar lesion despite the disappearance on the chest X-ray, and a right lower lobectomy was performed. Malignant cells remained in the scar lesion, but not in the lymph nodes. These findings suggested the effectiveness of neoadjuvant chemotherapy. This newly-designed chemotherapy procedure is necessary for patients with renal complications.
ISSN:	0385-0684